By Jay Richards
The Federalist
The risk in any grim line of work is that you get used to it — that true horrors cease to appear horrible. I assume the folks who clean up crime scenes and conduct autopsies get used to their work. Otherwise, they’d crack.
I spend my days studying a new line of business called “gender-affirming care.” That’s a euphemism for the current craze of treating teenagers who struggle with gender dysphoria. In response, doctors who practice “gender-affirming care” try to drug and cut these young bodies to fit their self-diagnosed internal sense of gender. This internal sense is called “gender identity.” Don’t ask for a better explanation. There isn’t one.
I’m so used to reading about “top surgeries,” “bottom surgeries,” and sterilized teenagers that I fear I’m growing jaded. Honestly, that’s a risk. But even I wasn’t prepared for the report on the “sex reassignment surgery” market just released by Grand View Research.
The U.S. market for such surgeries, we are told, “was valued at USD 1.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 11.23% from 2022 to 2030.” At that rate, the market revenue will grow to $5 billion at the end of this decade. Business is booming because of “rising incidences of gender dysphoria and the increasing number of people opting for gender confirmation surgeries.”
The report offers no commentary or explanation for this surprising fact.
The report goes on to repeat the common claims of gender ideologues, about how these surgeries “help” people with gender dysphoria — a claim for which there’s no good evidence. But they’re just repeating ad copy. Grand View’s expertise is in market analysis.
READ THE FULL STORY HERE!
